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Sustained androgen receptor signaling is a
determinant of melanoma cell growth potential and
tumorigenesis
Min Ma1*, Soumitra Ghosh1*, Daniele Tavernari2,3, Atul Katarkar1, Andrea Clocchiatti4,5, Luigi Mazzeo1, Anastasia Samarkina1,
Justine Epiney1, Yi-Ru Yu6, Ping-Chih Ho6, Mitchell P. Levesque7, Berna C. Özdemir8,9, Giovanni Ciriello2,3, Reinhard Dummer7, and
G. Paolo Dotto1,4,9
Melanoma susceptibility differs significantly in male versus female populations. Low levels of androgen receptor (AR) in
melanocytes of the two sexes are accompanied by heterogeneous expression at various stages of the disease. Irrespective of
expression levels, genetic and pharmacological suppression of AR activity in melanoma cells blunts proliferation and induces
senescence, while increased AR expression or activation exert opposite effects. AR down-modulation elicits a shared gene
expression signature associated with better patient survival, related to interferon and cytokine signaling and DNA damage/
repair. AR loss leads to dsDNA breakage, cytoplasmic leakage, and STING activation, with AR anchoring the DNA repair
proteins Ku70/Ku80 to RNA Pol II and preventing RNA Pol II–associated DNA damage. AR down-modulation or
pharmacological inhibition suppresses melanomagenesis, with increased intratumoral infiltration of macrophages and, in an
immune-competent mouse model, cytotoxic T cells. AR provides an attractive target for improved management of melanoma
independent of patient sex.
Introduction
Malignant melanoma is the fifth most common cancer in the
world, and its incidence is rising. Among the many prognostic
risk factors that have been proposed for the disease, one of the
most intriguing and least understood is sex (Nosrati and Wei,
2014). In fact, melanoma is an example of primary clinical sig-
nificance for investigating sex-related differences in cancer in-
cidence and survival, with the male population having greater
susceptibility than the female, across all ages (Nosrati and Wei,
2014). Although differences in lifestyle and behavior may ex-
plain the delay and higher disease stage in men at diagnosis, the
female survival advantage persists even after adjusting for these
and additional variables (histological subtypes, Breslow thick-
ness, and body site; Gamba et al., 2013; Joosse et al., 2013).
As for sexual dimorphism in other cancer types (Clocchiatti
et al., 2016), even for susceptibility to melanoma, differences in
sex hormone levels and/or downstream pathways are likely to
play a key role (Nosrati and Wei, 2014). Relative to sex protein
hormones, much more evidence exists on the impact of sex
steroid hormones on cancer development (Clocchiatti et al.,
2016). The great majority of accrued information for melanoma
relates to estrogen signaling, while much less is known about
androgen signaling.
In experimental settings, estrogen signaling was found to
restrict melanocyte proliferation, enhance differentiation, and
suppress melanoma development (Natale et al., 2016, 2018;
Ramelyte et al., 2017). In spite of the experimental evidence,
epidemiological studies on the interconnection between estro-
gen levels and melanoma development and progression yield
conflicting conclusions (Nosrati and Wei, 2014; Ramelyte et al.,
2017), which may be due, in part, to the difficulty in controlling
for estrogen levels, which vary with the menstrual cycle, onset
of menopause, use of oral contraceptives, and hormone re-
placement therapy. Additionally, the possible interplay between
estrogens and other hormones, specifically androgens, has not
been taken into consideration. An interplay with frequently
opposite effects between estrogen and androgen signaling has
been reported for several cell types (Clocchiatti et al., 2016),
which may extend to melanocytes.
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The androgen receptor (AR) is expressed in many cell types
and, while most studies have focused on prostate cancer, AR
signaling has been implicated in tumorigenesis in other organs,
specifically breast, bladder, kidney, lung, and liver (Chang et al.,
2014). Surprisingly little is known about the role of AR signaling
in melanoma. As early as 1980, it was proposed that differences
in androgen levels could explain the lower survival of male
melanoma patients than females (Rampen and Mulder, 1980).
Since then, however, only circumstantial pharmacological evi-
dence has been obtained, pointing to a positive role of AR sig-
naling in development of the disease (Nosrati and Wei, 2014).
For instance, in a human melanoma cell line expressing an
atypical form of AR, incubation with androgens significantly
stimulated proliferation, with effects that were reversed by
treatment with the androgen antagonist flutamide (or its active
metabolite hydroxyflutamide; Morvillo et al., 1995). The nonste-
roidal antiandrogen flutamide was also found to be effective in
diminishing tumor growth and increasing survival of nude mice
inoculated with human melanoma cells through possibly indirect
effects (Morvillo et al., 2002). In fact, others reported that ad-
ministration of flutamide increased murine splenocyte prolifera-
tion and IFN secretion in response to irradiated murine B16
melanoma cells, and when flutamide was administered with an
irradiated B16 vaccine, this combination improved the survival of
mice implanted with nonirradiated B16 cells (Hsueh et al., 2003).
Despite the above, genetic evidence in support of an intrinsic role
of AR signaling in melanoma development is missing, with the
possible exception of a study of a melanoma cell line with or
without infection with a single shRNA silencing vector, which
resulted in limited AR down-modulation (Wang et al., 2017). AR
signaling in this setting was implicated in the control of melanoma
cells’ invasive properties, without any effect on proliferation.
In this study, based on analysis of a large panel of clinical
samples and melanoma cells from both male and female patients,
we show that, irrespective of expression levels, genetic and
pharmacological suppression of AR activity triggersmelanoma cell
senescence and limits tumorigenesis, eliciting a gene expression
signature related to IFN and inflammatory cytokines and associ-
ated with better patients’ survival. Loss of AR activity in both
melanoma cells and tumors is sufficient to cause massive chro-
mosomal DNA breakage and leakage into the cytoplasm, with a
stimulator of IFN genes (STING)–dependent inflammatory sig-
naling cascade. Underlying these events, we find that AR is es-
sential in melanoma cells for anchoring the DNA repair proteins
Ku70/Ku80 to RNA polymerase II (Pol II) and preventing RNA Pol
II–associated DNA damage. Although at different levels, androgens
are produced in both male and female individuals, and AR tar-
geting provides an attractive therapy approach for improved
management of melanoma irrespective of patient sex.
Results
AR is heterogeneously expressed in melanocytic lesions and
melanoma cells
Melanoma tumors are characterized by distinct phenotypic
states and display significant intra- and intertumor heteroge-
neity (Tirosh et al., 2016). Double immunofluorescence (IF)
analysis of melanocytes in benign or dysplastic nevi or meta-
static melanoma versus melanocytes from flanking skin showed
consistently increased levels of AR expression in the melano-
cytic lesions, with heterogeneity of AR protein expression at the
single-cell level (Fig. 1 A and Fig. S1, A–D). Analysis of multiple
topographically distinct areas withinmultiple lesions showed no
significant intralesional heterogeneity in AR expression, while
confirming variations among lesions (Fig. 1 B and Fig. S2).
Similar IF analysis of melanoma tissue microarrays also showed
variable degrees of AR expression irrespective of stages of ne-
oplastic development or sex and age of patients (Fig. 1 C, Fig. S1
E, and Table S1). Immunohistochemical staining confirmed the
IF results with prevalent nuclear AR localization in lesions with
elevated and intermediate expression and more uneven locali-
zation when expressed at low levels (Fig. 1 D and Fig. S1 F).
Immunostaining of cultured cells also showed a variation in
AR protein expression among various melanoma cell lines and
primary melanoma cells derived from male or female patients,
with AR levels being uniformly low in primary melanocytes
(Fig. 1 E, Fig. S1 G, and Table S2). As observed in vivo, AR lo-
calization was largely nuclear in melanoma cells with elevated
expression, similar to LnCAP or 22RV.1 prostate cancer cell lines,
while in melanoma cell lines or primary melanocytes with low
AR levels, there was limited punctate nuclear localization with
prevalent perinuclear distribution (Fig. 1 E and Fig. S1 G).
Variations in AR expression were further confirmed by im-
munoblotting with two different antibodies, with a similar
pattern of bands, and by quantitative RT-PCR (RT-qPCR) analysis
of melanoma cell lines, early passage primarymelanoma cells, and
primary melanocytes, which were again found to express lower
AR levels (Fig. S1, H and I).
Sustained AR expression is required for melanoma cell
proliferation and self-renewal potential
The heterogeneous levels of AR expression raised the question of
its biological significance. Accordingly, we silenced AR expres-
sion in a panel of melanoma cells harboring either BRAF orNRAS
mutations individually and in combination with TP53, PTEN,
and/or CDK4 mutations (Fig. S3, A and B). Irrespective of basal
levels of AR expression, in all cases silencing of the gene by two
different shRNAs resulted in drastically reduced proliferation
and self-renewal as assessed by cell density, clonogenicity, and
sphere formation assays (Fig. 2, A–C; and Fig. S3, C–E). Effects
were paralleled by decreased DNA synthesis, induction of apo-
ptosis, and cellular senescence (Fig. 2, D–F; Fig. S3 F; and Fig. S4,
A and B). The shRNA gene silencing effects were suppressed
in melanoma cells concomitantly infected with an AR-
overexpressing lentivirus (Fig. 2 G and Fig. S4, C–E), which
was by itself sufficient to enhance proliferation of primary
melanocytes as well as melanoma cells with low AR expression
(Fig. 2 H).
As an alternative to shRNA-mediated gene silencing, we also
down-modulated AR expression by a CRISPR interference
(CRISPRi) system (Ho et al., 2017; Kearns et al., 2014), whereby a
dCas9-KRAB transcription repressor was directed to the AR
promoter region by two different single-guide RNAs (sgRNAs).
Mass infection of dCas9-KRAB–expressing melanoma cells with
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Figure 1. AR expression in melanoma cells. (A) Representative images and quantification of AR expression in cells of melanocytic lesions versus mela-
nocytes of flanking normal skin (stars) by double IF with antibodies against AR (red) and MelanA (green) for melanocyte identification. DAPI was used for
nuclear localization (blue). Shown are AR fluorescence signal intensity in arbitrary units (AU) per individual cells together with mean and statistical significance.
MelanA-positive cells, n ≥ 25, unpaired t test, ****, P < 0.001. Samples from male patients in this and following panels are indicated by asterisks. (B) Left:
Double IF staining of a primary melanoma lesion and topographically distinct areas (boxes 1, 2, and 3) analyzed for single-cell AR expression. Scale bars: 500
and 50 µm, respectively. IF images of cells in this and other lesions are shown in Fig. S2. Right: Quantification of nuclear AR fluorescence signal in individual
MelanA-positive cells (dots) from three topographically delimited areas per melanocytic lesion of different patients. Fluorescence intensity AU values per
individual cells are indicated together with the mean. MelanA-positive cells, n ≥ 50, unpaired t test, ****, P < 0.001. (C)Quantification of AR fluorescence signal
in MelanA-positive cells in a tissue microarray of different melanoma lesions (left) and metastatic and nonmetastatic forms (right). SSM, superficial spreading
melanoma; acral, acral lentiginous melanoma. Quantification was based on digitally acquired images of three independent fields per lesion (≥50 cells per field),
with averaged values per individual lesion shown together with mean. Quantification of samples divided by sex and age of patients is provided in Fig. S1 E.
Patient sample details provided in Table S1. n.s, not significant. (D) Immunohistochemical staining with anti-AR antibodies of melanomas with high versus
intermediate and low AR expression as assessed by double IF analysis in A. Scale bar: 30 µm. Lower-magnification images with MelanA staining of parallel
sections are shown in Fig. S1 F. (E) Quantification and representative images of nuclear AR expression by IF analysis of the indicated melanoma cell lines or
primary melanoma cells versus primary melanocytes (Mel a-f), and prostate cancer cell lines (LnCAp, 22RV.1) examining >100 cells per sample. Shown are
individual cells values (dots) together with mean ± SD. Scale bar: 10 µm. Additional images of cells are shown in Fig. S1 G.
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Figure 2. AR down-modulation suppresses melanoma cell proliferation potential. (A) Left: WM1366 melanoma cells infected with two AR-silencing
lentiviruses versus empty vector control were analyzed by cell density assays (CellTiter-Glo) on the indicated days after selection. Shown are luminescence
intensity values relative to day 1 ± SD; one-way ANOVA with Dunnett’s test. Cultures, n = 9; all experiments repeated three times. *, P < 0.05. Right: Heatmap
results with additional melanoma cells. Efficiency of AR gene silencing and individual plots for all heatmap results are shown in Fig. S3 (A and B). (B and C)
Clonogenicity and sphere formation assays of the same WM1366 together with heatmap results with additional melanoma cells. Results are shown as in-
dividual cultured dishes together with mean ± SD; one-way ANOVA with Dunnett’s test. Cultures, n = 9; all experiments repeated three times. *, P < 0.05; ***,
P < 0.005. (D–F)Melanoma cells with or without AR silencing as in the previous panels were tested by EdU labeling assay (D), annexin V staining (E), or SA-β gal
activity (F). Shown are individual plots for WM1366 melanoma cells together with mean ± SD; one-way ANOVA with Dunnett’s test; heatmap results for all
other indicated lines. Cultures, n = 6; all experiments repeated two times. **, P < 0.01; ****, P < 0.001. (G) Right: IF analysis of AR expression in A375 cells
stably infected with an AR-overexpressing (AR oe) lentivirus or vector control and superinfected with an AR-silencing lentivirus or corresponding control. Scale
bar 10 µm. Quantification of results, also in cells infected with a second AR-silencing lentivirus, together with mRNA expression measurements are shown in
Fig. S4 (C and D). Left: Clonogenicity and SA-β gal assays of A375 melanoma cells with or without AR silencing and overexpression as indicated. Data are shown
as mean ± SD; one-way ANOVA with Dunnett’s test. Cultures, n = 6; all experiments repeated two times. ***, P < 0.005. Cell density, EdU labeling, and
apoptosis assays for the same cells are shown in Fig. S4 E. (H) Proliferation live-cell imaging assays (IncuCyte) of the indicated primary melanocyte strains
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two lentiviruses with AR-targeting sgRNAs significantly reduced
AR protein levels, decreased clonogenicity, and induced cellular
senescence, reproducing the effects of AR gene silencing (Fig. 2,
I–K).
Modulation of melanoma and melanocyte proliferation by
pharmacological inhibition and agonist stimulation
AR is a fundamental target for therapy of metastatic prostate
cancer, and inhibitors with multiple mechanisms of action and
efficacy have been developed (Crawford et al., 2018). Treatment
of different melanoma cell lines with several AR inhibitors, in-
cluding one that functions through both ligand-competitive and
noncompetitive mechanisms, AZD3514 (Loddick et al., 2013),
and another, pure ligand competitive inhibitor, enzalutamide
(Bambury and Scher, 2015), exerted similar growth-suppressive
effects, although at different doses (Fig. 3 A). The first compound
exhibited a greater potency, which we found to be associated, as
previously reported for LNCaP cells (Loddick et al., 2013), with
down-modulation of AR expression in two of three tested cell
lines (Fig. S4 F). The AZD3514 inhibitory effects were confirmed
by treatment of a larger panel of melanoma cell lines and pri-
mary melanoma cells with different levels of AR expression,
consistent with the basal protective function investigated below
(Fig. 3, B and C; and Fig. S4, G and H).
We recently reported that suppression of AR activity in hu-
man dermal fibroblasts (HDFs) by a ligand-competitive inhibitor
induces expression of a battery of tumor-promoting cancer-
associated fibroblast effector genes, similarly to silencing of
the gene (Clocchiatti et al., 2018). To assess the net effects of AR
inhibitors on melanoma cells in the presence of surrounding
HDFs, we used an in vitro cancer/stromal cell expansion assay
based on the coculture in Matrigel of fluorescently labeled cells
(Clocchiatti et al., 2018). As shown in Fig. 3 D, expansion of
melanoma cells admixed with HDFs was significantly reduced
by treatment with the AR inhibitor AZD3514, consistent with
the efficacy of this compound in the in vivo assays shown
further below.
Conversely to the growth suppressing effects of the AR in-
hibitors, proliferation of primary melanocytes and melanoma
cells in charcoal-strippedmediumwas significantly enhanced by
treatment with the AR agonist dihydrotestosterone (DHT) in a
dose-dependent manner (Fig. 3 E and Fig. S4 I). Proliferation of
other melanoma cell lines and primary melanoma cells in
charcoal-stripped medium was also enhanced by DHT stimula-
tion (Fig. 3 F and Fig. S4, J and K) and, when they were cultured
under very sparse conditions, their expansion was very highly
dependent on the hormone (Fig. S4 L). Thus, besides being re-
quired, increased AR signaling is a positive determinant of
melanoma cell proliferation.
The melanoma AR-dependent gene signature is of clinical
relevance
AR controls transcription through both direct and indirect DNA
binding mechanisms (Matsumoto et al., 2013). We performed
transcriptomic analysis of three different melanoma lines, two
with BRAF and one with NRAS mutations, with or without AR
silencing with two different lentiviruses. By gene set enrich-
ment analysis (GSEA; Subramanian et al., 2005), gene signatures
related to IFN-, cytokine-, and STING-signaling pathways were
the most significantly associated with the gene expression pro-
files resulting from AR silencing (Fig. 4 A and Table S4) together
with those related to DNA repair and apoptosis.
Next, we established an AR gene-silencing signature of 155
genes, which were significantly and concordantly modulated by
AR silencing in all three melanoma cell lines (Fig. 4 B and Table S3).
The most down-modulated gene was CDCA7L, coding for a tran-
scriptional repressor and c-MYC interacting protein with shared
oncogenic function (Hendrix et al., 2014; Tian et al., 2013), while the
most up-regulated genes included several with key immunomod-
ulatory functions, such as ICAM1 (Adutler-Lieber et al., 2018), TLR4
and TLR6 (Rakoff-Nahoum and Medzhitov, 2009), DDX58 (RIG-1),
and IFIH1 (melanoma differentiation–associated factor 5; Brisse and
Ly, 2019; Fig. 4 B and Table S3).
The analysis was extended to a panel of other melanoma cell
lines and primary melanoma cells with different levels of
AR expression by RT-qPCR. CDCA7L expression was down-
modulated while CDKN1A was up-regulated in all cells by AR
silencing, consistent with the observed induction of cellular se-
nescence. Intercellular adhesion molecule 1 (ICAM1) was consis-
tently up-regulated together with IL6, a potent proinflammatory
cytokine (Fig. 4 C). As for “canonical” genes involved inmelanoma
progression, differentiation marker genes such as TyR and TYRP1
were either up- or down-modulated by AR silencing in the various
cell lines, and so were the MITF master regulatory gene (Roider
and Fisher, 2014) and ZEB2, coding for a transcription factorwith a
role in melanogenesis upstream of MITF expression (Denecker
et al., 2014). AXL, coding for a receptor tyrosine kinase impli-
cated in melanoma aggressive behavior (Revach et al., 2019), was
mostly down-modulated (Fig. 4 C).
To assess the clinical significance of the findings, we exam-
ined the gene expression profiles of a cohort of 469 cutaneous
melanomas in the Cancer Genome Atlas (TCGA) dataset Skin
Cutaneous Melanoma (SKCM). Tumors were stratified as having
positive or negative association scores with the AR gene-
silencing signature that we established. Tumors with positive
scores had significantly higher patient survival than those with
negative scores (log-rank test, P = 2.6 × 10−5; Fig. 4 D). The
findings remained significant after correcting for age, sex, ge-
nomic subtype, and primary or metastatic status (multivariate
(c and f) and melanoma cells (M14) stably infected with an AR-overexpressing lentivirus versus empty vector control. Cells were plated in triplicate wells in 96-
well plates followed by cell density measurements (four images per well every 4 h for 128 h). Cultures, n = 3; Pearson r correlation test. *, P < 0.05; **, P < 0.01.
(I) Immunoblot analysis of AR expression in dCas9-KRAB–expressing melanoma cells (WM1366, SKMEL28, and A375) infected with lentiviruses expressing two
sgRNAs targeting the AR promoter region (sgAR1 and sgAR2) versus scrambled sgRNA control (sgCTR) for 3 d. (J and K) Parallel cultures of cells as in I were
tested by clonogenicity (J) and SA-β gal (K) assays on triplicate dishes, starting on day 3 after sgRNA expression. Cultures, n = 3 biological replicates; one-way
ANOVA with Dunnett’s test. *, P < 0.05; **, P < 0.01; ***, P < 0.005; ****, P < 0.001.
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Cox regression, P = 0.002). Analysis of the transcriptomic pro-
files by the Epic algorithm (Racle et al., 2017) was used to esti-
mate the proportion of cancer-infiltrating immune cells. A
significantly higher proportion of infiltrating B cells, CD4+ and
CD8+ T cells, and macrophages was found in melanomas with a
positive association with the AR gene-silencing signature than in
those with a negative association (Fig. 4 E). The results were
validated and refined with an independent approach, CI-
BERSORTx (Newman et al., 2019), showing that tumors with a
positive association with the AR silencing signature were selectively
enriched for M1-like versus M2-like macrophages, and for CD4+
memory T cells (Fig. S5 A).
AR loss triggers genomic DNA breakage, cytoplasmic leakage,
and STING-dependent gene expression
The iLINCS (Integrative LINCS; http://www.ilincs.org/ilincs/)
portal allows comparative analysis of transcriptional profiles of
various cell lines in response to different drugs. A significant
concordance was found between the AR silencing gene sig-
nature and the iLINCS-derived transcriptional profiles of A375
Figure 3. Modulation of melanoma cell proliferation by pharmacological inhibition and agonist stimulation. (A) Proliferation live-cell imaging assays
(IncuCyte) of the indicated melanoma cell lines treated with the AR inhibitors AZD3514 (2, 5, and 10 µM) or Enzalutamide (5 and 10 µM) versus DMSO control.
Number of wells, n = 3; Pearson r correlation test. *, P < 0.05; **, P < 0.01; ***, P < 0.005. (B) WM1366 melanoma cells treated with AZD3514 versus DMSO
control were analyzed by cell density assays (CellTiter-Glo) on the indicated days. Data are shown as mean ± SD; one-way ANOVA with Dunnett’s test.
Cultures, n = 9; all experiments repeated three times. *, P < 0.05. Right: Heatmap results with additional melanoma cells, with individual plots shown in Fig.
S4 G. (C) The indicated melanoma cells were treated with AZD3514 (5 and 10 µM) versus vehicle control (DMSO) followed by cell density determination by
crystal violent staining 7 d later. Data are shown as mean ± SD; one-way ANOVA with Dunnett’s test. Cultures, n = 3. ****, P < 0.001. (D) In vitro cancer/stromal
cell expansion assays, with RFP-expressing A375 melanoma cells cocultured with GPF-expressing HDFs with or without treatment with AZD3514 (10 µM) or
DMSO control for 4 d. Shown are representative images and quantification of melanoma cell expansion (percentage area covered by melanoma cells per field).
Each dot represents one analyzed field. Number of fields, n = 12; two-tailed paired t test, ****, P < 0.001. Scale bar: 30 µm. (E) Proliferation live-cell imaging
assays (IncuCyte) of two primary melanocyte strains cultured in medium with charcoal-stripped serum and treated with DHT at the indicated concentrations
versus DMSO control. Number of wells, n = 3; Pearson r correlation test. *, P < 0.05; **, P < 0.01. Results of a similar assay with another primary melanocyte
strain and melanoma cells are shown in Fig. S4 (I and K). (F) Cell density assays (CellTiter-Glo) of WM1366 melanoma cells in medium with charcoal-treated
serum and treated with DHT (20 nM) versus DMSO control for the indicated days. Data are shown as mean ± SD; one-way ANOVAwith Dunnett’s test. Cultures,
n = 9, all experiments repeated three times. *, P < 0.05. Right: Heatmap results with additional melanoma cells, with individual plots shown in Fig. S4 J.
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Figure 4. Global analysis of AR-regulated genes in melanoma cells and clinical relevance. (A) GSEA of transcriptional profiles elicited by AR silencing in
WM1366, SKMEL28, and WM115 melanoma cells by two different lentiviruses versus empty vector control, using a predefined set of gene signatures related to
cellular processes and signaling pathways (Broad Institute, http://software.broadinstitute.org/gsea/msigdb/collections.jsp#H). Cells were analyzed 5 d after
infection by Clariom D array hybridization. Top: Plot distribution of gene signatures related to IFNα, inflammatory response, and DNA repair pathways. Genes
are ranked by signal-to-noise ratio in AR-silenced versus control melanoma cells; position of individual genes is indicated by black vertical bars; enrichment
score is in green. Bottom: Relevant gene sets most significantly associated with AR silencing gene signature are indicated together with the corresponding false
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melanoma cells treated with several AR inhibitors, as well as a
number of DNA-damaging agents targeting the topoisomerase
2 (TOPO2) and TOPO1 enzymes (Fig. 4 F and Table S5). Consis-
tent with these findings, comet assays showed that AR gene si-
lencing was sufficient to induce massive chromosomal DNA
breakage in several melanoma cells, irrespective of endogenous
levels of AR expression (Fig. 5 A), which was accompanied by
induction of γ-H2AX, a marker of the DNA damage response
(Bonner et al., 2008; Fig. 5, B and C). In parallel, AR silencing
resulted in the abundant release of double-stranded DNA
(dsDNA) fragments into the cytoplasm, together with increased
expression and aggregation of the STING protein, a cytosolic
DNA sensor with an important role in innate immunity (Chen
et al., 2016; Fig. 5, B and C). Similar observations were also ob-
tained by CRISPRi downmodulation of AR expression and treat-
ment with the AR inhibitor AZD3514 (Fig. 5, D and E; and Fig. S4,
M and N). The findings are of functional significance, as induction
of IL6 and ICAM1, two STING target genes with key immune-
modulatory functions (Chen et al., 2016), was suppressed at both
protein and mRNA levels by concomitant AR and STING knock-
down (Fig. 6, A–C). The link between AR loss and ensuing events
was further supported in that chromosomal DNA damage and
leakage into the cytoplasm, STING activation, and IL6 and ICAM1
induction were all suppressed in cells in which AR gene silencing
was counteracted by overexpression (Fig. 6, D and E).
AR plays an essential function in anchoring the Ku70 and Ku80
DNA repair proteins to RNA Pol II and preventing RNA Pol
II–associated DNA damage
A number of indirect mechanisms could be responsible for
chromosomal DNA breakage resulting from loss of AR activity.
However, an attractive possibility is that AR also physically as-
sociates with proteins involved in the maintenance of genomic
integrity and contributes to their function. A significant amount
of endogenous DNA damage occurs in cells in association with
gene transcription (Tubbs and Nussenzweig, 2017). The proc-
essive function of RNA Pol II is coupled with the release of
dsDNA torsional stress by TOPO-mediated cleavage and reseal-
ing, with the association of DNA repair proteins such as Ku70
and Ku80 as part of a protective mechanism (Tubbs and
Nussenzweig, 2017). Direct binding to Ku70 and Ku80 to AR
has been previously reported (Mayeur et al., 2005), raising the
attractive possibility that AR is involved in anchoring Ku70 and
Ku80 to the transcription apparatus. Coimmunoprecipitation
(co-IP) and proximity ligation assays (PLAs) with antibodies
against AR and these proteins showed that they effectively as-
sociate in various melanoma cell lines (Fig. 7, A and B). A similar
number of PLA complexes were detected in cells with different
total AR protein levels, with PLA signal being abolished by
shRNA-mediated AR gene silencing as well as treatment with the
AR inhibitor AZD3514, supporting the specificity of the assays
(Fig. 7, C and D). Complexes of Ku70 and Ku80 with RNA Pol II
were detected by PLA assays with antibodies against total RNA
Pol II, as well as specific for the Pol II phosphorylated form (CTD,
Ser2) involved in transcription elongation (Phatnani and Greenleaf,
2006; Fig. 7 E, F). Importantly, the association of Ku70 and Ku80
with Pol II was drastically reduced by AR gene silencing, pointing to
an essential anchoring function of the AR protein (Fig. 7, E and F).
Loss of Ku70–RNA Pol II association in cells with loss of AR was
mirrored by a drastic increase in foci of DNA damage associated
with RNA Pol II, as detected by PLA assays with antibodies against
γ-H2AX (Fig. 7 G). Overall, these findings are consistent with a
model whereby loss of AR results in detachment of Ku70/Ku80
DNA repair proteins from the RNA Pol II complex and increased
dsDNA damage at sites of transcription (Fig. 7 H). This, in combi-
nation with additional, more indirect mechanisms, leads to massive
dsDNA breakage and leakage into the cytoplasm with activation of
the STING-dependent signaling cascade.
AR loss or inhibition results in reduced tumorigenicity with
enhanced immune cell infiltration
To assess the in vivo significance of the findings, we used an
orthotopic model of melanoma formation based on the intra-
dermal injection of melanoma cells embedded in Matrigel
(Clocchiatti et al., 2018), which enables the assessment of early
steps of tumor formation and expansion. Using this assay, we
found that tumorigenic expansion and proliferative activity of
multiple melanoma cell lines (WM1366, A375, and SKMEL28)
discovery rate q values. The full list of significantly associated gene signatures is provided in Table S4. (B) Volcano plot of shared transcriptional changes in
WM1366, SKMEL28, and WM115 melanoma cells with or without AR silencing. The x axis shows the log2 fold-change, and the y axis shows −log10 of statistical
significance (P value). A false discovery rate threshold of 0.05 and fold-change thresholds of −1 and 1 are indicated by dashed red lines. Each dot represents one
gene. Gray and red dots correspond to genes not significantly or nonconcordantly modulated in the three melanoma lines, respectively. Black dots show genes
above thresholds that are concordantly up- or down-regulated in all three cell lines and compose the AR-silencing gene signature used for further analysis. A
few selected genes among the most significantly differentially expressed ones are indicated. The list of 155 genes associated with AR-silencing gene signature is
provided in Table S3. (C) Expression of the indicated genes in multiple melanoma cell lines with or without AR silencing by two different lentiviruses versus
empty vector control. (D) Association of the AR-silencing gene signature in melanoma cells (as obtained in B) with patients’ survival in SKCM dataset. Positive
and negative association scores for each patient were computed from RNA-sequencing data with GSVA R package. Kaplan–Meier curves show that melanomas
with positive association with the AR-silencing signature (red, n = 251) have better survival than those with negative association (blue, n = 218); P = 2.6 × 10−5,
log-rank test. (E) Fraction of tumor-infiltrating immune cells estimated by EPIC R package analysis of SKCM dataset, using default reference profile in tumors
with positive and negative association with the AR-silencing signature (red and blue box plots, respectively). Cell fractions for B cells, CD4+ T cells, CD8+ T cells,
and macrophages are reported (each dot representing one tumor). Outliers with cell fraction >0.15 are not shown. The additional enrichment scores of
signature matrix associated with 22 different immune cell types determined by CIBERSORTx are shown in Fig. S5 A (nonsignificant subpopulations are not
shown). ****, P < 0.001. (F) Bar plot reporting the concordance between the melanoma AR-silencing gene signature and iLINCS expression profiles of A375
cells treated with compounds targeting AR (blue), TOPO1, and TOPO2A (red). Perturbagens of each class are sorted by concordance (P < 0.0001), and names of
chemical compounds are reported on the x axis along with molecular targets. A list of compounds eliciting gene expression profiles with concordance co-
efficient >0.6 with AR-silencing signature is reported in Table S5.
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Figure 5. Loss of AR function induces DNA breakage, cytoplasmic dsDNA leakage, and STING activation. (A) Comet assays of melanoma cell lines with
or without AR silencing on day 1 after selection. Shown are representative images of WM1366 melanoma cells together with quantification of percentage tail
DNA (Comet Score) in five different melanoma cell lines. Scale bar: 10 µm. Number of cells, n =125; one-way ANOVA; ****, P < 0.001. (B) Representative double
IF images of WM1366 cells with or without AR silencing stained with antibodies against γ-H2AX (green) and phalloidin (gray; upper panel), dsDNA (red) and
STING (green; middle panel), and ICAM1 (red; lower panels). Scale bar: 10 µm. (C)Quantification of nuclear γ-H2AX, cytoplasmic DNA, ICAM1 IF signal intensity,
and percentage of STING-positive cells in the indicated panel of melanoma cell lines with or without AR silencing. More than 100 cells were counted in each
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was significantly reduced, in male and female mice, by AR si-
lencing (Fig. 8, A and B; and Fig. S5, B and C). In parallel, AR
silencing resulted in cytoplasmic dsDNA release, STING aggre-
gation, and ICAM1 induction (Fig. 8, C–E). While host macro-
phages were mostly absent in tumors formed by control cells,
they actively infiltrated tumors formed by cells with silenced AR
(Fig. 8 F and Fig. S5, B and C).
These findings are likely of translational significance, as
suppression of tumor cell proliferation, together with dsDNA
cytoplasmic release, STING activation, and ICAM1 induction,
condition. Results are expressed as mean ± SD. Cultures, n = 3; one-way ANOVA with Dunnett’s test, **, P < 0.01, ***, P < 0.005. (D and E) Double IF image
analysis of a panel of melanoma cells treated with AZD3514 (10 µM) versus DMSO control for 2 d. Shown are representative images (D) and quantification (E)
of the results as in C. Cultures, n = 3; two-tailed paired t test, *, P < 0.05; **, P < 0.01, ***, P < 0.005.
Figure 6. Loss of AR function induces STING-dependent gene expression. (A and B)Double IF analysis of WM1366melanoma cells transfected with STING
and/or AR-silencing siRNAs versus scrambled controls, with antibodies against STING (upper panel, green), IL6, and ICAM1 (middle and lower panels, red) and
phalloidin staining for cell border delimitation (gray). Shown are representative images (A) and quantification (B) of STING, IL6, and ICAM1 fluorescence signal
intensity per cell, 48 h after transfection. Each dot corresponds to mean fluorescence intensity per cell. Number of cells, n = 25; paired t test, ***, P < 0.005,
****, P < 0.001. Scale bar: 10 µm. (C) RT-qPCR analysis of STING, IL6, and ICAM1 mRNA expression in the indicated melanoma cell lines 48 h after transfection
with STING and/or AR-silencing siRNAs versus scrambled controls. Each bar corresponds to mean expression levels per melanoma cell line. Data are repre-
sented as mean ± SD. Number of strains, n = 3; one-way ANOVA with Dunnett’s test, *, P < 0.05, **, P < 0.01. (D) Representative double IF images and
quantification of γ-H2AX expression (green) and cytoplasmic dsDNA leakage (red) in A375 cells stably infected with an AR-overexpressing (AR oe) or control
lentivirus and superinfected with two AR-silencing lentiviruses versus control. Scale bar: 10 µm. Data are from triplicate experiments; each dot represents one
experiment. Cultures, n = 3; one-way ANOVA with Dunnett’s test, **, P < 0.01. (E) Representative double IF images and quantification of STING (green) and
ICAM1 (red) expression in A375 cells with or without AR overexpression and silencing as in D. Independent experiments, n = 3; one-way ANOVA with Dunnett’s
test, **, P < 0.01.
Ma et al. Journal of Experimental Medicine 10 of 21
Androgen signaling loss suppresses melanoma growth https://doi.org/10.1084/jem.20201137
Figure 7. AR anchors the Ku70 and Ku80 DNA repair proteins to RNA Pol II and prevents RNA Pol II–associated DNA damage. (A) Co-IP analysis with
anti-AR and anti-RNA pol II antibodies in WM1366 melanoma cells and immunoblotted for indicted proteins. (B) PLAs of WM1366 melanoma cells with an-
tibodies against AR and Ku70 and nonimmune IgGs as specificity control. Red fluorescence puncta resulting from the juxtaposition of anti-AR and anti-Ku70/
Ku80 antibodies were visualized by confocal microscope with concomitant DAPI nuclear staining. Shown are representative images and quantification of the
number of puncta per cell. For this and following panels, n (cells per condition) > 50; ***, P < 0.005; ****, P < 0.001, 2-tailed unpaired t test. (C) PLAs of AR and
Ku70 association in melanoma cell lines with elevated (WM1366 and SKMEL28) versus low (SKMEL5) levels of total AR protein (as shown in Fig. 1 E), with or
without shRNA-mediated AR gene silencing. ***, P < 0.005; ****, P < 0.001. (D) PLAs of AR and Ku70 association in the same melanoma cell lines as in C with
or without treatment with the AR inhibitor AZD3514 (10 µM for 48 h). ***, P < 0.005; ****, P < 0.001. (E and F) PLAs of the indicated melanoma cell lines with
or without AR gene silencing with antibodies against Ku70 or Ku80 and total RNA Pol II (E) or elongating form (CTD Ser2 phosphorylated; F). ****, P < 0.001.
(G) PLAs of melanoma cells with or without AR gene silencing as in F, with antibodies against the elongating form of RNA Pol II and γ-H2AX. Shown are better
representative images. Scale bars: 10 µm. ****, P < 0.001. (H) Diagrammatic model of the AR anchoring function, required for Ku70/Ku80 association to the
RNA Pol II transcription complex and prevention of transcription-associated DNA damage.
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was also observed by treatment of tumor-bearing animals with
the AR inhibitor AZD3514 (Fig. 9, A–D) or pretreatment of cells
before injection into the animals (Fig. S5 E). Even in this case,
the results were accompanied by increased macrophage infil-
tration (Fig. 9, E and F).
To further elucidate whether AR expression can influence
the immunogenicity of melanoma cells and the immune in-
filtrates in the tumor microenvironment (Wu et al., 2020), we
used an immunocompetent model system based on the injection
of the mouse melanoma cell line YUMM1.7 (Meeth et al., 2016)
into syngeneic mice (BL6 strain). Silencing of the mouse AR gene
by two different shRNA lentiviral vectors or treatment with AR
inhibitors resulted in a significant reduction of proliferation,
similar to what we observed with the human cells (Fig. 10, A–D).
In vivo, upon intradermal injection into immune-competent
mice, melanoma cells with silenced AR formed much smaller
tumors than controls, with substantially reduced melanoma cell
density and proliferative index (Fig. 10, E and F). Dissociation
of tumor cells followed by FACS analysis showed a significant
increase of macrophages (CD45+ Gr-1− F4/80+ CD11b+) in AR-
silenced YUMM1.7 melanomas, consistent with what we ob-
served with human cells in immune-compromised mice
(Fig. 10 G). While the total number of CD4+ T cells (CD45+ CD3+
CD4+) was not significantly different, that of CD4+ regulatory
T cells (CD45+ CD3+ CD4+ FoxP3+) was significantly decreased in
in AR-silenced YUMM1.7 melanomas (Fig. 10 H). Percentage
levels of total CD8+ T cells (CD45+ CD3+ CD8+) did not vary
consistently; however, the activated fraction (CD44+ population)
was significantly increased, with a lesser expression of co-
inhibitory molecules, LAG3 and PD1, which are highly expressed
by exhausted T cells (Yang et al., 2017; Fig. 10, I and J). Thus, in a
syngeneic mouse model, decreased tumorigenicity of melanoma
cells with AR loss is associated with enhanced modulation of
innate and acquired immunity.
Discussion
The impact of sex hormone signaling in cancer development in
organswith nonreproductive functions is still poorly understood
(Clocchiatti et al., 2016). We have shown here that sustained AR
Figure 8. Suppression of melanoma formation by AR silencing.WM1366 melanoma cells with or without AR silencing were tested by parallel intradermal
Matrigel injections into NOD/SCIDmale and female mice (five per group; data of male mice in red). (A) Tumor size, measured by digital caliper (mass = [length ×
width × height] × π/6) together with representative H&E images of the retrieved lesions 16 d after injection. (B–E) Double IF analysis of lesions with antibodies
against AXL, for melanoma cell identification, quantification of KI67-positive (B) or cytoplasmic dsDNA–positive (C) cells, and mean fluorescence signal intensity
of STING (D) and ICAM1 expression (E). Shown are representative images of AXL-positive cells (AXL signal not shown in C–E) stained with antibodies against
the other markers, together with relative quantification (>50 cells in three to five fields). (F) Representative images and quantification of the number of F4/80-
positive macrophages per AXL-positive tumor area, counting in each case three to four fields. Similar determination of CD45 positive cells is shown in Fig. S5 B.
Control versus experimental lesions, n = 10; two-tailed paired t test, *, P < 0.05; **, P < 0.01; ***, P < 0.005. Scale bar: 10 µm. Similar tumorigenicity ex-
periments with A375 and SKMEL28 cells with or without shRNA-mediated AR silencing is shown in Fig. S5 (C and D).
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signaling is key for melanoma cell proliferation potential and
tumorigenesis in cells from both male and female individuals.
Irrespective of its expression levels, AR plays an essential
function in preventing cellular senescence and genomic DNA
damage. This is in contrast with previous reports on prostate
cancer cells, in which AR inhibition, while synthetically lethal
with other treatments (Karanika et al., 2017; Li et al., 2017), does
not appear to be sufficient to induce DNA damage and down-
stream events by itself. In fact, a number of reports indicate that
DNA damage can be induced in prostate cancer cells by over-
stimulation of AR activity (Chatterjee et al., 2019; Lin et al.,
2009).
A number of convergent mechanisms are likely to be impli-
cated in the AR dependence of melanoma cells, as revealed by
shRNA-mediated silencing of the gene, down-modulation by a
CRISPRi approach, and pharmacological inhibition by AR in-
hibitors. Modulation of multiple genes under AR control is likely
to be involved in the suppression of proliferation that results
from AR loss, including up-regulation of CDKN1a, an inducer of
cellular senescence and direct AR negative target (Clocchiatti
et al., 2018), and down-modulation of CDCA7L, coding for a
c-MYC–interacting protein with pro-oncogenic function in
other cell types (Hendrix et al., 2014; Tian et al., 2013). Opposite
modulation of these genes could contribute to the growth-
promoting effects exerted by increased AR activity in mela-
noma cells as well as primary melanocytes. We previously
showed that in dermal fibroblasts, as in melanoma cells, loss of
AR activity by either gene silencing or pharmacological ap-
proaches results in cellular senescence together with a senescence-
associated secretory phenotype that promotes tumorigenesis of
neighboring cancer cells (Clocchiatti et al., 2018). Thus, AR loss
can have a two-edged sword effects on cancer cells versus sur-
rounding stromal cells, while inducing cellular senescence in
both. In melanoma development, the consequences on cancer
cells are likely prevalent, since in coculture assays of melanoma
cells and dermal fibroblasts, a potent AR inhibitor exerted net
beneficial effects that paralleled those observed in vivo, in an
orthotopic model of melanoma formation.
Besides suppression of proliferation, another major conse-
quence of AR gene silencing or pharmacological inhibition was
dsDNA breakage in the absence of additional exogenous insults,
with dsDNA leakage into the cytoplasm and ensuing STING
activation. Together with a number of possible mechanisms
related to AR control of gene transcription, we have found that
Figure 9. Suppression ofmelanoma formation by AR inhibition. (A–F) RFP-expressing A375 melanoma cells were injected intradermally into 10male mice.
3 d after injection, mice were treated by oral gavage with either AZD3514 (50 mg/kg) or DMSO vehicle alone for 12 consecutive days. IF analysis was used to
assess KI67 (A) and cytoplasmic dsDNA (B) positivity and STING (C) and ICAM1 (D) expression levels in melanoma cells (RFP-positive) together with numbers of
juxtaposed leukocytes (E) and macrophages (F), as assessed by staining for the CD45 and F4/80markers, respectively. Shown are quantifications together with
representative images, including one (F) showing engulfment of fragmented RFP-positive melanoma cells into F4/80-positive macrophages in lesions of mice
treated with the AZD3514 inhibitor. Control versus experimental lesions, n = 4 and 10; unpaired t test, **, P < 0.01; ***, P < 0.005, ****, P < 0.001. Scale bar: 10
µm (A–F). Similar tumorigenicity experiments with injection of AZD3514-pretreated WM1366 cells are shown in Fig. S5 E.
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AR plays a more direct and essential role in anchoring the DNA
repair proteins Ku70/Ku80 to RNA Pol II and preventing RNA
Pol II–associated DNA damage. A similar number of AR-Ku70
and AR-dependent Ku70/80-RNA Pol II complexes could be
detected in melanoma cell lines with substantially different total
AR levels, suggestive of a minor pool of this protein being
selectively involved in Ku70/80 anchoring function. A direct
association of Ku70/Ku80with AR has already been reported for
Figure 10. Suppression of mouse melanoma formation and immune cells recruitment by AR gene silencing. (A–C) Mouse melanoma cells YUMM1.7
were infected with two AR-silencing lentiviruses versus empty vector control, 24 h after selection, by determination of ARmRNA levels (A), cell density (B), and
EdU labeling assay (C). (D) YUMM1.7 cells were treated with AZD3514 (10 µM) versus DMSO control followed by cell density assays on the indicated days after
treatment. Data are shown as mean ± SD; one-way ANOVA with Dunnett’s test, *, P < 0.05; **, P < 0.01; ****, P < 0.001. Cultures, n = 6. (E and F) RFP-
expressing YUMM1.7 cells with or without AR silencing were tested by parallel intradermal Matrigel injections into C57BL/6JOIaHsd male and female mice (four
per group; data of male mice in red). Shown are representative H&E and IF images of the retrieved lesions 14 d after injections and determination of tumor
mass (E) and percentage of KI67-positive RPF-expressing YUMM1.7 cells. For F, >50 cells in three to five fields per lesion; control versus experimental lesions,
n = 8; two-tailed paired t test, *, P < 0.05. Scale bar: 500 µm (E) and 100 µm (F). (G–J) FACS analysis of tumor dissociated cells for total numbers of macrophage
cells (CD45+ Gr-1− F4/80+ CD11b+; G), percentage of macrophages in the CD45+ cell populations (left and right panels, respectively; H), percentage of CD4+
T cells (CD45+ CD3+ CD4+) over total CD45+ leukocytes and fraction of regulatory T cells (Tregs; CD45+ CD3+ CD4+ FoxP3+)within CD4+ T cells, and percentage
of CD8+ T cells (CD45+ CD3+ CD8+) over total CD45+ leukocytes (I) and of CD44+ population of CD8+ T cells together with mean fluorescence intensity (MFI)
levels of LAG-3 and PD-1 staining in CD44+ fraction cells (J). Control versus experimental lesions, n = 8; two-tailed paired t test, *, P < 0.05; **, P < 0.01; n.s, not
significant.
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prostate cancer cells, in which, however, Ku70 and Ku80 were
implicated in control of AR-dependent transcription (Mayeur
et al., 2005), rather than AR being required for Ku70/Ku80 as-
sociation with RNA Pol II. While Ku70/Ku80 bind a number of
transcription proteins (Fell and Schild-Poulter, 2015; Mo and
Dynan, 2002), their dependence on AR for effective associa-
tion with the transcription complex is a surprising finding of
biological importance. The resulting enhancement of endoge-
nous DNA damage suggests that already approved AR inhibitors
could be used in new combination approaches for melanoma
treatment. In support of this possibility are our further findings
that, in the iLINCS database, similar gene expression profiles
are triggered by treatment of melanoma cells with AR inhibitors
and conventional DNA-damaging agents, specifically TOPO
inhibitors.
The STING proinflammatory signaling cascade activated by
loss of AR function can be an important determinant of tumor
infiltration by immune cells (An et al., 2019; Chen et al., 2016;
Woo et al., 2015). Increased cancer cell recognition and elimi-
nation by the immune system can be highly beneficial in a
substantial fraction of melanoma patients (Sharma and Allison,
2015). This is consistent with bioinformatic analysis of large
melanoma datasets sorted by the AR gene-silencing signature
that we have established, as well as experimental findings with
tumors formed by melanoma cells with or without AR loss. As
such, AR inhibition could provide an approach to ameliorate
response to immune checkpoint inhibitors, especially of
“immune-excluded” and “immune desert” tumors (Chen and
Mellman, 2017), in which sex hormone differences could be
involved (Özdemir and Dotto, 2019).
In melanoma samples of the TCGA database, there is a 4% AR
gene mutation frequency. However, the vast majority are
missense gene mutations that do not coincide with those re-
ported in the AR gene mutation database, and their functional
significance will have to be assessed. Additional complexities
to consider are polymorphisms of the AR gene (Ryan and
Crespi, 2013) and the possible involvement of unrelated
membrane-associated androgen sensor proteins (Thomas,
2019) that may converge with AR signaling in promoting the
disease.
As suggested many years ago (Rampen and Mulder, 1980),
differences in androgen levels between male and female pop-
ulations are a likely determinant of their different susceptibility
to the disease. However, our findings clearly indicate that mel-
anoma cells of both male and female individuals are equally
dependent on sustained AR signaling for proliferation, mainte-
nance of genomic stability, and tumorigenesis. Sexual dimor-
phism in this as in other cancer types cannot be solely attributed
to hormonal differences and/or their impact on individual cell
types (Clocchiatti et al., 2016). At the level of individuals, the
interplay between hormonal and genetic determinants of sex
specification, as well as the extreme complexities of nuclear
hormone receptor interactions, can result in a continuous
spectrum of susceptibility to various diseases (Dotto, 2019). Ir-
respective of sex, our findings point to AR signaling as a sig-




A list of melanoma cell lines and primary melanoma cells de-
rived from male and female patients is provided in Table S2.
Early-passage (5–6) primary melanoma cell cultures (M121008,
M141022, and M131206) were established from discarded mela-
noma tissue samples by University Research Priority Program
(URPP) Live Cell Biobank (University of Zurich) with required
institutional approvals. WM1366, WM983A, WM1862, and
WM1552C melanoma cells were a gift from Meenhard Herlyn
(The Wistar Institute, Philadelphia, PA). The YUMM1.7 mela-
noma cell line was provided by P-C. Ho. No further authenti-
cation of these cell lines was performed. Cell morphology and
growth characteristics were monitored during the study and
compared with published reports to ensure their authenticity.
All melanoma cell lines and patient-derived primary melanoma
cells were maintained in DMEM (Thermo Fisher Scientific)
supplemented with 10% (vol/vol) FBS (Thermo Fisher Scientific)
and 1% penicillin-streptomycin. Primary melanocytes were
prepared from discarded human skin samples from abdomino-
plasty or circumcision at the departments of Plastic Recon-
structive Surgery or Pediatrics, Lausanne University Hospital,
with required institutional approvals (UNIL: CER-VD 222/12)
and informed consent. All cells used in this study were deter-
mined to be negative forMycoplasma before experiments. All cell
lines were used within five passages after thawing.
Cell manipulations and treatments
Lentiviral particle production and infections were performed as
described previously (Dull et al., 1998). Details of the lentiviral
shRNA vectors and sgRNA vectors used are provided in Table S6.
Two different shRNAs directed against human or mouse AR in
the pLKO.1 lentiviral vector were used to silence the gene.
Melanoma cells were infected with lentiviruses for 2 h; 2 d after
infection, cells were selected with 1 µg/ml of puromycin for 3 d.
RNA or protein samples were collected 5 d after infection.
Mouse YUMM1.7 melanoma cells used for AR gene silencing
were previously stably infected with RFP-expressing lentiviral
vector with blasticidin selection.
For siRNA silencing experiments, melanoma cells were
transfected with AR- and/or STING-silencing siRNAs versus
scrambled control siRNAs by INTERFERin (409; Polyplus
Transfection) according to the manufacturer’s instructions. The
details of the siRNAs used in this study are provided in Table S6.
For AR overexpression and rescue experiments, melanoma
cells were stably infected with a blasticidin-resistant lentiviral
vector for constitutive AR expression (a gift of Karl-Henning
Kalland, Bergen University, Bergen, Norway) or vector control.
After selection, the AR-overexpressing melanoma cells were
superinfected with an AR-silencing or corresponding lentivirus
control and selected for puromycin resistance as described
above. The cell proliferation assays were performed 5 d after the
second infection.
For CRISPRi downmodulation of AR expression, A375 mela-
noma cells were stably infected with a dCas9-KRAB–expressing
lentivirus (pHAGE EF1a dCas9-KRAB; Kearns et al., 2014), using
puromycin for selection. Cells were subsequently superinfected
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with lentivirus (Lenti Guide-hygro-eGFP; Ho et al., 2017) har-
boring scramble sgRNA or two sgRNAs targeting different re-
gions of the AR promoter. Cells were analyzed 3 d after infection.
The sequences of the sgRNAs are provided in Table S6.
For AR inhibitor treatment, 24 h after seeding, melanoma
cells were treated with indicated concentrations of AZD3514
(Adooq Biosciences), Enzalutamide (Selleckchem), or DMSO
solvent control as indicated. For DHT treatment experiments,
melanoma cells werewashed four times in PBS after seeding and
cultured for 48 h in phenol red–free DMEM complemented with
charcoal-treated FBS before treatments with DHT (Milli-
poreSigma) or vehicle control (EtOH) as indicated.
Cell-based assays
Cell proliferation assays were performed by measuring the
production of ATP using the CellTiter-Glo luminescent assay
(Promega) as per the manufacturer’s instructions. The lumi-
nescence signals for each time point were normalized to the
signal obtained at day 0.
5-Ethynyl-29-deoxyuridine (EdU) incorporation assays were
performed using Click-iT Plus EdU Imaging Kit (Thermo Fisher
Scientific) following the manufacturer’s instructions. The
number of EdU-positive cells was analyzed, and the data were
represented as percentage of EdU-positive cells.
For clonogenicity assays, cells were plated on 60-mm dishes
(1,000 cells/well; triplicate wells/condition) and cultured for 7 d.
Colonies were fixed with 4% formaldehyde and stained with 1%
crystal violet. The number of clones was counted using ImageJ
(National Institutes of Health).
For sphere formation assays, melanoma cells were plated
onto 8-well chamber slides (Corning) precoated with Matrigel
(Corning). In brief, chambers were coated with 100 µl Matrigel
per well and incubated for 1 h at 37°C to polymerize. 1,000
melanoma cells were plated in each well. The number of sphe-
roids was assessed 7 d after plating through an EVOS Cell
Imaging System (Thermo Fisher Scientific).
For IncuCyte cells proliferation assays, 1,000 melanoma cells
per condition were seeded in triplicate into each well of a 96-
well plate and allowed to attach for 12 h. The plates were
mounted on IncuCyte Zoom System (Essen Bioscience), and cells
were allowed to grow for the next 6 d. Images were captured at
four different sectors of each well every 2 h for 6 d, and cell
confluence was calculated by IncuCyte Zoom software.
For apoptosis assays, dead and proapoptotic cells were as-
sessed using the Annexin Kit (BD Biosciences). In brief, before
fixation, cells were washed with annexin-binding buffer, fol-
lowed by incubation for 15 min at room temperature (RT) with
annexin-Cy5 dye for staining of proapoptotic cells. After an-
nexin incubation, cell were fixed with 4% formaldehyde and
counterstained with DAPI.
Senescence-associated β-galactosidase (SA-β-Gal) activity
was assessed by the use of a commercially available chromogenic
assay kit (Cell Signaling) as per the manufacturer’s instructions.
Comet assays
The extent of double-strand DNA breaks generated with or
without AR silencing in individual melanoma cells was assessed
using alkaline comet assay (single-cell electrophoresis) as de-
scribed previously (Bottoni et al., 2019). Images were obtained
with a Zeiss AxioImager Z1. The percentage of tail DNA per
nuclei was calculated using Comet Score 1.6.1.13 software.
IF and immunohistochemistry staining
IF staining of tissue sections and cultured cells was performed as
described previously (Kim et al., 2017). Briefly, frozen tissue
sections or cultured cells on glass coverslips were fixed in cold
4% paraformaldehyde for 15 min at RT. Paraffin-embedded
sections were subjected to deparaffinization and antigen re-
trieval using a citrate-based buffer system. Samples were
washed with PBS, followed by permeabilization with 0.1% Triton
X-100 in PBS for 10 min and incubated with 2% BSA in PBS for
2 h at RT. Primary antibodies were diluted in fluorescence di-
lution buffer (2% BSA in PBS, pH 7.6) and incubated overnight at
4°C. A list of primary antibodies and dilutions used for IF is
provided in Table S6. After washing three times in PBS, samples
were incubated with donkey fluorescence conjugated secondary
antibodies (Invitrogen) for 1 h at RT. After washing with PBS,
slides were mounted with Fluoromount Mounting Medium
(Sigma-Aldrich) after nuclear DAPI staining. Control staining
without the primary antibodies was performed in each case to
subtract background and set image acquisition parameters. IF
images were acquired with a Zeiss AxioVision or Zeiss LSM880
confocal microscope with 20× or 40× oil-immersion objectives.
Axiovision or Zen Black software was used for acquisition and
processing of images. For fluorescence signal quantification, ac-
quired images for each color channel were imported into ImageJ
and quantified using the functions “measurement” or “particle
analysis” for selection of areas or cells of interest. The fluores-
cence intensities are indicated as arbitrary units.
For the melanoma tissue microarray, the mean intensity of
AR fluorescence in melanoma cells for each microbiopsy was
measured using ImageJ. A binary image was created from the
MelanA-positive cells by setting a threshold to consider only
MelanA signal with pixel intensity between 36 and 255. A mask
was then derived from the MelanA-positive area to mark mel-
anoma cells, and the mean intensity of AR fluorescence was
measured inside the mask. Data for melanoma tissue array data
were plotted as average AR intensity of three fields per spotted
tumor sample, each field comprising a group of ∼50–60 cells.
Each dot represents one clinical tissue sample.
Immunohistochemical analysis was performed using a pre-
viously described protocol for prostate cancer cells (Li et al.,
2018). Briefly, 4-µm-thick sections of formalin-fixed paraffin-
embedded tissue blocks from different melanomas were sub-
jected to deparaffinization using xylene, hydrated in a graded
series of ethanol solutions, and subjected to antigen retrieval
with 10 mM Tris/EDTA buffer solution (pH 9.0) at 100°C for
20 min. Parallel sections were permeabilized, blocked, and in-
cubated with anti-AR antibody or anti-MelanA antibodies.
Chromogenic detection was performed using a peroxidase-
conjugated secondary antibody (30 min) and DAB reagents (5
min). Tissue sections were counterstained with 0.1% hematoxylin.
Immunohistochemical staining was performed by an experienced
laboratory of pathology in our institution. Immunohistochemical
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images were acquired with a Zeiss AxioVision microscope
with 20× objective. Axiovision software was used for acquisition
and processing of images.
Immunoblotting and RT-qPCR
Cells were lysed in radioimmunoprecipitation assay buffer
(10 mM Tris-Cl, pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.1%
sodium deoxycholate, 0.1% SDS, 140 mMNaCl, and 1 mM PMSF)
or LDS buffer (Thermo Fisher Scientific). Equal amounts of
proteins were subjected to immunoblot analysis. Membranes
were sequentially probed with different antibodies as indicated
in the figure legends, using an enhance chemiluminescence kit
(Thermo Fisher Scientific) for detection. Details of antibodies
used in this study are provided in Table S6. RT-qPCR analysis
was performed as described previously (Kim et al., 2017). A list
of primers used in this study is provided in Table S6.
PLAs
PLAs were performed with a Duolink kit with provided reagents
and buffers (DUO92101; Sigma-Aldrich) using the following
protocol. Melanoma cells were seeded on glass coverslips in a 24-
well plate. After washing with PBS three times, cells were fixed
with cold 4% paraformaldehyde for 15 min at RT. The fixed cells
were washed with PBS, followed by permeabilization with 0.1%
Triton X-100 in PBS for 15 min at RT, incubation in blocking
buffer (provided with the kit) for 2 h at 37°C in a humidified
chamber, and incubation with different primary antibodies
(against target proteins to be analyzed) diluted in antibody di-
luents overnight at 4°C. Cells were subsequently washed in
buffer A three times for 15 min and incubated with the PLA
probes for 1 h at 37°C in a humidified chamber. This was fol-
lowed by a 10 min wash in buffer A, a ligation reaction at 37°C
for 1 h, and twomorewashes (10 and 5min) in buffer A. Samples
were then incubated with the amplificationmix for 2 h at 37°C in
a darkened humidified chamber, followed by washing with 1×
buffer B (10 min) and 0.01× buffer B (1 min) and processing with
mounting media. Cells were counterstained with DAPI, and
images were acquired with a Zeiss LSM880 confocal micro-
scope. The number of PLA puncta (dots) per cell/nucleus was
quantified using the fluorescent particle analysis with ImageJ.
Details of the antibodies used in PLA assays are provided in
Table S6.
Co-IP analysis
WM1366 melanoma cells were harvested by trypsinization. Cells
were resuspended in ice-cold co-IP buffer (50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1% Na-deoxycholate,
0.05% SDS, and protease inhibitor) and lysed by mild sonication
(three 5-s pulses). The cell debris were removed by centrifuga-
tion, and the supernatant was subjected to extensive DNase I
digestion. Co-IP was performed by incubating 500 µg of the
lysate with 4 µg of anti-AR (5153S; CST) or anti-RNA pol II
(ab26721; Abcam) antibodies in 500 µl co-IP buffer for 8 h at 4°C.
Amock reactionwas also performed by incubating rabbit IgG (as
control) with the lysate. Prewashed Protein A magnetic beads
were added, and the incubation was continued for another 1 h.
The beads were washed three times with 1 ml of co-IP buffer,
resuspended in SDS-PAGE sample loading buffer, and incubated
for 20min at 98°C. The samples were resolved on 8% SDS-PAGE,
and immunoblotting was performed with anti-AR (06-680;
Merck Millipore), anti-RNA pol II (ab26721; Abcam), and anti-
Ku70 (GTX101820; GeneTex) antibodies. VeriBlot IP Detection
Reagent (HRP; ab131366; Abcam) was used as secondary anti-
body (1:200 dilution) to selectively detect target protein bands,
without interference from the denatured IgG heavy and light
chains. Details of the antibodies used are provided in Table S6.
Transcriptomic analysis
The transcriptional changes elicited in WM1366, SKMEL28, and
WM115 melanoma cells with or without AR-silencing with two
different lentiviruses versus empty vector control were assessed
by Clariom D GeneChip array analysis (Thermo Fisher Scien-
tific). 5 d after infection, RNA was extracted from the melanoma
cells using Direct-zol RNA MiniPrep kit (Zymo Research) cou-
pled with DNase treatment, and RNA quality was verified by
Bioanalyzer (Agilent Technologies). 50 ng of total RNA was used
as input for the preparation of single-strand cDNA using the
GeneChip WT PLUS Reagent Kit (Thermo Fisher Scientific).
Targets were then fragmented and labeled with the GeneChip
WT Terminal Labeling Kit (Thermo Fisher Scientific) and hy-
bridized on Human Clariom D GeneChip arrays (Thermo Fisher
Scientific) at the iGE3 Genomics Platform, University of Geneva
(Geneva, Switzerland). Data obtained were analyzed using TAC
software (v4.0). The data generated in this study have been
deposited to the public functional genomics data repository GEO,
accession no. GSE138486.
GSEA for GeneChip microarray data was conducted using
GSEA software with default parameters. Curated gene sets were
obtained from the Molecular Signatures Database (MSigDB
version 5.2, http://www.broadinstitute.org/gsea/msigdb/). A
list of enriched pathway gene sets is provided in Table S4.
Construction of the AR-silencing gene signature
Raw microarray expression data were preprocessed with TAC
software, obtaining gene-level expression values from signal
space transformation/robust multiarray average summariza-
tion. Ensemble IDs were mapped to gene symbols with Biomart.
A paired differential expression analysis between control (n = 3)
and shAR (n = 6) conditions was performed with Limma (default
parameters), pairing together samples from each cell line. The
AR silencing signature was constructed as the list of genes up- or
down-regulated upon AR silencing, i.e., genes showing an ad-
justed P value < 0.05 and an absolute log fold-change >1 in the
overall analysis as well as in each cell line separately.
Computation of AR-silencing signature scores in TCGA SKCM
dataset
Level 3 gene expression and clinical data for TCGA SKCM
projects were downloaded from the National Institutes of Health
Genomic Data Commons Data Portal (https://portal.gdc.cancer.
gov). In case both primary and metastatic samples were present
for the same patient, only the primary sample was retained.
TPM (transcripts per million) values were transformed as log2
(TPM + 1). Scores for the sets of genes up- and down-regulated
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were computed with the R package GSVA v1.30.0 using default
parameters. The difference between these scores was computed
to obtain a unified score for the total AR-silencing gene signature
(comprising both up- and down-regulated genes) for each pa-
tient. Each tumor was assigned a positive (+) or negative (−)
score relative to the unified AR-silencing gene signature.
Survival analysis
The difference between the survival of patients with a positive
(+) versus negative (−) score for the AR silencing gene signature
was tested with a log-rank test implemented in the R package
survival v2.43-3. A Cox regression from the same package was
used to account for the following covariates: age, sex, primary or
metastatic status, and genomic subtype (BRAF mutant, RAS
mutant, NF1 mutant, or triple wild-type).
EPIC and CIBERSORTx analyses
Cell type fractions for bulk RNA-sequencing melanoma samples
from TCGA SKCMwere computed with EPIC v1.1.5 using default
parameters and CIBERSORTx using LM22 signature matrix and
B-mode batch correction. Differences between melanomas en-
riched and not enriched for the AR-silencing gene signature
were tested with Wilcoxon rank-sum tests.
iLNCS analysis
The analysis of concordance between our in-house AR silencing
gene signature and iLINCS chemical perturbagen signatures was
performed by interrogating the iLINCS data portal (http://www.
ilincs.org/ilincs/). Briefly, the iLINCS web application computes
concordance as the Pearson correlation coefficient between the
fold-changes of the genes in common (n = 21) between the query
signature and the precomputed iLINCS signatures. Signatures
with correlation >|0.2| and P < 0.05 are extracted and sorted by
concordance. A list of top iLINCS signatures with concordance
score >0.65 is shown in Table S5.
Tumorigenesis experiments
Intradermal back injections of indicated melanoma cells were
performed in 6–8-wk-old male and female NOD SCID mice
(NOD.CB17-Prkdcscid/J; Jackson Laboratory). In brief, 106 mel-
anoma cells (WM1366, A375, and SKMEL28) infected with AR
silencing versus control lentiviruses were injected (29-gauge
syringe) with Matrigel (Corning; 70 µl per injection) intrader-
mally in parallel into the left and right side of mice. Mice were
sacrificed, and Matrigel nodules were retrieved for tissue
analysis 16 d after injection.
For in vivo AZD3514 treatment experiments, RFP-expressing
A375 melanoma cells (1 × 106) were intradermally injected with
Matrigel solution in the back skin of 10 male NOD SCID mice. 3 d
after injection, mice were treated with either 100 µl of AZD3514
(50 mg/kg, per mouse, group of five mice) or Captisol (Ligand
Technology) as vehicle control (group of fourmice) for 12 consecutive
days by oral gavage. The body weight of the mice was measured
regularly during the treatment. Mice were sacrificed, and Matrigel
noduleswere retrieved for tissue analysis at the end of the treatment.
Alternatively, melanoma cells were treated with either
AZD3514 (10 µM) or DMSO for 12 h in culture and injected
intradermally in mice together with Matrigel as described
above. The tumors were allowed to grow for 2 wk, and nodules
were retrieved for tissue analysis at the end of the treatment.
Intradermal back injections of YUMM1.7-RFP cells were
performed in 6- to 8-wk-old male and female mice (C57BL/6J;
Jackson Laboratory). In brief, 5 × 105 melanoma cells infected
with AR silencing versus control lentiviruses were injected with
Matrigel (Corning; 60 µl per injection; 29-gauge syringe) in-
tradermally in parallel into the left and right side of mice. Mice
were sacrificed, and Matrigel nodules were retrieved for flow
cytometry analysis 14 d after injection. All mice were housed in
the animal facility of the University of Lausanne.
Tumor digestion, cell isolation, and flow cytometric analysis
Tumors were minced in RPMI with 2% FBS, i.v. collagenase
(0.5 mg/ml; Sigma-Aldrich), and DNase (1 µg/ml; Sigma-
Aldrich) and digested at 37°C for 45 min. The digested samples
were then filtered through a 70-µm cell strainer and washed with
FACS buffer (PBS with 2% FBS and 2 mM EDTA). The cell pellets
then incubatedwith ACK lysis buffer (Invitrogen) to lyse red blood
cells. Next, viable cells in single-cell tumor suspensions were
further enriched by density gradient centrifugation (800 g,
30 min) at RT with 48% and 80% Percoll (GE Healthcare) and
collected from the interphase of the gradient. FACS analysis was
performed using an LSRII (BD Biosciences). Data were analyzed
using FlowJo. The following antibodies were used for flow cy-
tometry: anti-CD3 (17A2), anti-CD4 (RM4-5), anti-CD8α (53-6.7),
anti-CD11b (M1/70), anti-CD45 (104), anti-Gr-1 (RB6-8C5), anti-
FoxP3 (FJK-16s), anti-CD44 (IM7), anti-F4/80 (BM8), anti-LAG3
(C9B7W), anti-PD1 (RMP1-30), and anti-Arg1 (A1exF5). Cell pop-
ulations were identified based on the following expression
markers: CD4 T cells, CD45+ CD3+ CD4+; CD8 T cells, CD45+ CD3+
CD8+; regulatory T cells, CD45+ CD3+ CD4+ FoxP3+; and macro-
phages, CD45+ Gr-1− F4/80+ CD11b+. Antibody details, including
commercial sources, are provided in Table S6.
Statistical analysis
Statistical testing was performed using Prism 8 (GraphPad
Software). Data are presented as mean ± SEM or SD, as indicated
in the legends. Statistical significance for comparing two ex-
perimental conditions was calculated by two-tailed t tests. For
multiple comparisons of more than two conditions, one-way
ANOVA was used, with Dunnett’s test to compare different
test conditions to the same control. For tumorigenicity assays,
wherever possible, individual animal variability was minimized
by contralateral injections in the same animals of control versus
experimental combinations of cells. No statistical method was
used to predetermine sample size in animal experiments, and no
exclusion criteria were adopted for studies and sample collec-
tion. No exclusion criteria were adopted for animal studies and
sample collection. No randomization was used, and the re-
searchers involved in the study were not blinded during sample
obtainment or data analysis.
Study approval
Melanocytes were prepared from discarded human skin samples
from abdominoplasty or circumcision at the Department of
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Plastic Reconstructive Surgery or Pediatrics, Lausanne Univer-
sity, with required institutional approvals (UNIL: CER-VD 222/
12) and informed consent. Benign nevi, dysplastic nevi, primary
and metastatic skin sections, and melanoma tissue microarray
slides were obtained from the Live Cell Biobanks of the URPP
“Translational Cancer Research” (Mitchell P. Levesque, Univer-
sity Hospital Zurich). All samples were obtained as surplus
material from consenting patients (Ek. 647/800), and the ex-
periments were approved by the Kantonal ethics committee of
Zürich (Kantonale Ethikkommission Zürich, approval no.
KEK.Zh.Nr.2014-0425). No access to sensitive information was
provided. All animal studies were performed according to Swiss
guidelines for the use of laboratory animals, with protocols ap-
proved by the University of Lausanne animal care and use
committee and the veterinary office of Canton Vaud (animal
license no. 1854.4f/1854.5a).
Online supplemental material
Fig. S1 shows double IF analysis of patient-derived melanocytic
lesions; AR expression across age and between sexes in a mel-
anoma tissue microarray; immunohistochemical analysis of AR
expression in patient-derived melanocytic lesions; IF analysis of
AR expression in different melanoma cell lines and primary
human melanocytes with prostate cancer cells as comparison;
AR protein expression in different melanoma cell lines and
primary human melanocytes as detected by two different anti-
bodies; and AR mRNA expression in different melanoma cell
lines and primary human melanocytes. Fig. S2 shows double IF
analysis of patient-derived melanocytic lesions. Fig. S3 shows
silencing of AR in different melanoma cell lines; suppression of
melanoma proliferation and self-renewal potential by AR si-
lencing; and EdU incorporation assay in melanoma cells with or
without AR silencing. Fig. S4 shows apoptosis and senescence
assays in melanoma cells with or without AR silencing; that AR
overexpression suppresses AR silencing effects; growth-
suppressive effects of AR inhibitors on melanoma cells; and
growth-stimulatory effects of DHT treatment of melanoma cells.
Fig. S5 shows prevalence of stromal and immune cells in TCGA
SKCM samples with and without enrichment for the AR-
silencing gene signature; that AR silencing inhibits WM1366,
A375, and SKMEL28 melanoma tumorigenesis; and that AZD3514
pretreatment inhibitsWM1366melanoma tumorigenesis. Table S1
is a summary of patient information of tissuemicroarray. Table S2
is a summary of a panel of human melanoma cell lines used in
this study. Table S3 lists 155 genes up- or down-modulated by
AR silencing in three melanoma cell lines (WM1366, SKMEL28,
and WM115) from transcriptomic profiling. Table S4 lists gene
sets significantly associated with differentially expressed genes
in melanoma cells upon AR gene silencing. Table S5 lists per-
turbagens with concordance with AR signatures, including the
associated P values from iLINCS database. Table S6 lists re-
agents and resources.
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Figure S1. AR expression analysis of patient-derived melanocytic lesions and melanoma cells. (A–D) Double IF images of benign nevi (A and B),
dysplastic nevi (C), and metastatic melanoma (D) in parallel with flanking skin stained with anti-MelanA (green) and anti-AR (ab74272; red) antibodies.
Highlighted in the lower panels are representative MelanA-positive cells and areas used for quantification in Fig. 1 A. Scale bar: 10 µm. (E) Quantification of AR
fluorescence signal in MelanA-positive cells in a tissue microarray of melanoma patients divided by age or sex. Quantification was based on digitally acquired
images of three independent fields per clinical lesion (minimum of 50 cells per field) on the arrays. Results are expressed as average values for each lesion (dots)
together with mean across years of age (left) or sex (right) of patients. n.s, not significant. (F) Immunohistochemical staining with anti-MelanA and anti-AR
(ab74272) antibodies of parallel sections of different melanomas with high, intermediate, and low levels of AR expression as quantified by double IF analysis in
Fig. 1 B. Shown are representative images, with only the enlarged boxed areas shown in Fig. 1 D. Scale bar: 50 µm. (G) Representative IF images of the indicated
prostate cancer cells lines (LnCaP and 22RV.1), melanoma cell lines and primary melanoma cells with high (WM1366, WM1552C, and WM983A) and low
(MM131206 and SKMEL5) AR expression, and primary human melanocytes (strain a) stained with anti-AR (red) antibody (D6F11) and DAPI (blue) nuclear
staining. Scale bar: 10 µm. (H) Immunoblot analysis of AR expression in melanoma cell lines (A375, SKMEL28, WM1366, WM115, and M14) and primary human
melanocytes with two different antibodies in parallel with prostate cancer cell lines (LnCaP and 22RV.1) as comparison. All extracts were run in two parallel gels
and blotted, respectively, with anti-AR (D6F11; left) or anti-AR (PG-21; right) antibodies. Shown are low- and high-exposure images of the same blots, for better
AR detection in highly expressing prostate cancer versus melanoma cells. (I) RT-qPCR analysis of ARmRNA expression in a panel of melanoma cell lines (red),
early-passage primary melanoma cells (blue), and primary human melanocytes (gray). Results are expressed as relative to RRLP0 values.
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Figure S2. Double IF analysis of patient-derived melanocytic lesions. (A–D) IF staining of benign nevi (A, patients 1 and 2), dysplastic nevi (B, patients 3
and 4), primary melanoma (C, patient 6), and metastatic melanoma (D, patients 7, 8, and 9) skin tissues with anti-MelanA (green) and anti-AR (ab74272; red)
antibodies, and topographically distinct areas (boxes 1, 2, and 3) used for single-cell AR expression quantification in Fig. 1 B. Shown are representative low- and
high-magnification images of the areas used for quantification. Scale bar: 2 mm and 20 µm, respectively.
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Figure S3. AR down-modulation suppresses melanoma cell growth. (A) Down-modulation of AR expression in a panel of melanoma cell lines and primary
melanoma cells (M121008, MM131206, and MM141022) infected with two AR-silencing lentiviruses versus empty control as assessed by RT-qPCR after se-
lection. Data are shown as mean ± SD, one-way ANOVA with Dunnett’s test, *, P < 0.05; **, P < 0.01; ***, P < 0.005; ****, P < 0.001. Cultures, n = 6.
(B) Immunoblot analysis of AR protein expression in different melanoma cell lines with or without AR gene silencing as in A. Shown are the immunoblots of AR
protein levels after densitometric scanning of the autoradiographs, using actin signal for normalization (lower panels). (C) Cell density assays (CellTiter-Glo)
were performed with the indicated melanoma cell lines and primary melanoma cells (M121008, MM131206, and MM141022) infected with two AR-silencing
lentiviruses versus empty vector control. Results are presented as luminescence intensity values relative to day 1. Data are shown as mean ± SD, one-way
ANOVA with Dunnett’s test, **, P < 0.01; ***, P < 0.005. Cultures, n = 9. (D–F) Colony formation, sphere formation, and EdU incorporation assays with
indicated melanoma cell lines with or without AR silencing. Shown are the results of three independent experiments quantifying in each case three culture
dishes per condition (indicated by dots, mean ± SD). Results are presented as mean ± SD, one-way ANOVA with Dunnett’s test, **, P < 0.01; ***, P < 0.005;
****, P < 0.001. Cultures, n = 9.
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Figure S4. Rescue of AR-silencing effects, pharmacological inhibition, and agonist stimulation. (A and B) Apoptosis and senescence assays in melanoma
cells with or without AR silencing. Indicated melanoma cell lines infected with two AR-silencing lentiviruses versus empty vector control were tested by
AnnexinV staining (A) and SA-β-GAL staining (B) after selection. AnnexinV- and SA-β-GAL–positive cells were counted using ImageJ. Shown are representative
images and results of two independent experiments quantifying in each case three culture dishes per condition (indicated by dots, mean ± SD), one-way
ANOVA with Dunnett’s test, *, P < 0.05; **, P < 0.01; ***, P < 0.005, ****, P < 0.001. Cultures, n = 6. (C–E) Concomitant AR overexpression suppresses AR-
silencing effects. A375 cells stably infected with a lentiviral vector for constitutive AR expression versus LacZ control and superinfected with two AR-silencing
lentiviruses versus vector control for 5 d. Shown is a violin plot quantifying AR IF signal intensity (C), with corresponding representative images shown in
Fig. 2 G. Cells per condition, n > 20, one-way ANOVA with Dunnett’s test, ****, P < 0.001. (D) Quantification of AR mRNA expression by RT-qPCR analysis of
A375 cells with or without AR overexpression and silencing as in C. The same samples were analyzed for levels of CDKN1A expression as a marker/effector of
cellular senescence induced by AR gene silencing. (E) The same melanoma cells as in C and D were tested by cell density assays (CellTiter-Glo), EdU incor-
poration assays, or apoptosis by annexin V staining. For each condition, cells were tested in duplicated culture dishes, with all experiments repeated three
times. Data are shown asmean ± SD, one-way ANOVAwith Dunnett’s test, **, P < 0.01; ***, P < 0.005. Cultures, n = 6. (F and G)Growth-suppressive effects of
AR inhibitors on melanoma cells. (F) Immunoblot analysis of AR protein expression in the indicated melanoma cell lines treated with AZD3514 (10 µM for 48 h)
versus DMSO control. (G) Cell density assays (CellTiter-Glo) of the indicated melanoma cell lines and primary melanoma cells (MM130926 and MM141022)
treated with AZD3514 (10 µM) versus solvent control (DMSO). Cells were plated on triplicate wells in 96-well dishes followed by cell density/metabolic activity
measurements on the indicated days after treatment. Results are presented as luminescence intensity values relative to day 1. Data are shown as mean ± SD,
*, P < 0.05; **, P < 0.01. t test. Cultures, n = 6. (H) EdU labeling assays of the indicated melanoma cells treated with AZD3514 (10 µM) versus solvent control
(DMSO) on day 5 after treatment. Data are shown as mean ± SD, t test, **, P < 0.01; ***, P < 0.005. Cultures, n = 5. (I and J) Growth-stimulatory effects of DHT
treatment of melanoma cells. (I) Proliferation live-cell imaging assays (IncuCyte) of the primary melanocytes (strain f) and SKMEL5 melanoma cells treated with
different doses of DHT (5, 10, and 20 nM) versus DMSO control. Cultures, n = 3; Pearson r correlation test, *, P < 0.05. (J) Cell density assays (CellTiter-Glo) of
the indicated melanoma cell lines and primary melanoma cells (MM130926 and MM141022) treated with the AR agonist DHT (20 nM) versus solvent control
(DMSO) on the indicated days after treatment. Results are presented as luminescence intensity values relative to day 1. (K) Proliferation live-cell imaging
assays of the indicated melanoma cells treated with DHT (20 nM) versus DMSO control. Cultures, n = 3; Pearson r correlation test, *, P < 0.05; **, P < 0.01.
(L) Cell density assays of the indicated melanoma cells tested under very sparse conditions. Cells were cultured in medium with charcoal-treated serum for
48 h followed by plating at very low numbers (500 cells per 60-mm dish) in the same medium ± treatment with DHT (10 and 20 nM) versus solvent control
(DMSO) for 7 d. Data are represented as relative cell density as quantified by ImageJ analysis of crystal violet–stained dishes. one-way ANOVA with Dunnett’s
test, *, P < 0.05; **, P < 0.01; ***, P < 0.005. Cultures, n = 3. (M and N)Quantification of nuclear γ-H2A and cytoplasmic DNA IF signal intensity in the indicated
melanoma cells with or without CRISPRi-mediated downmodulation of AR expression as shown in Fig. 2 I. More than 100 cells were counted in each condition.
Results are expressed as mean. Cultures, n = 3; one-way ANOVA with Dunnett’s test, ****, P < 0.001.
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Figure S5. Suppression of melanoma formation by AR silencing or inhibition. (A) Prevalence of stromal and immune cells in TCGA SKCM samples with
and without enrichment for the AR-silencing gene signature. Heatmaps reporting mean fractions of significantly prevalent (Wilcoxon rank-sum test,
Bonferroni-adjusted P < 0.05) stromal and immune cell types (columns) for TCGA SKCM samples with AR-silencing signature up or down (rows) obtained using
CIBERSORTx. Red intensity is proportional to the mean cell fraction, which is also reported in each entry. (B) Double IF analysis of lesions from Fig. 8 A with
antibodies against AXL, for melanoma cell identification and CD45-positive cells. Shown is the quantification together with representative images of CD45-
positive cells per AXL-positive tumor area, counting in each five fields, five male mice and five female mice; data of male mice in red. Scale bars: 20 µm. ***, P <
0.005. (C) AR silencing inhibits A375 melanoma tumorigenesis. Top: Tumor size, measured by digital caliper (mass = [length × width × height] × π/6) together
with representative low-magnification H&E images of the retrieved lesions. Middle: Double IF analysis of lesions with antibodies against MelanA (green), for
melanoma cell identification, and Ki67-positive cells. Shown are representative images of MelanA-positive cells stained with antibodies against the other
markers, together with relative quantification (counting in each case >50 cells in three to five fields on digitally retrieved images, using ImageJ). Bottom: Double
IF analysis of lesions with antibodies against MelanA, CD45, for melanoma cells, and hematopoietic cell identification, respectively. Shown are representative
images together with quantification of number of F4/80-positive cells per MelanA-positive tumor area, counting in each case three to four fields. Control
versus experimental lesions, n = 20; two-tailed paired t test, *, P < 0.05; **, P < 0.01; ***, P < 0.005. Scale bars: 10 µm. (D) AR silencing inhibits SKMEL28
melanoma tumorigenesis. Top: Tumor size, measured by digital caliper (mass = [length × width × height] × π/6) together with representative low-
magnification H&E images of the retrieved lesions. Scale bars: 100 µm. Middle: Double IF analysis of lesions with antibodies against MelanA (green), for
melanoma cell identification, and Ki67-positive cells. Shown are representative images of MelanA-positive cells stained with antibodies against the other
markers, together with relative quantification (counting in each case >50 cells in three to five fields on digitally retrieved images, using ImageJ). Bottom: Double
IF analysis of lesions with antibodies against MelanA, CD45 for melanoma cells, and hematopoietic cell identification, respectively. Shown are representative
images together with quantification of number of CD45-positive cells per MelanA-positive tumor area, counting in each case three to four fields. Control versus
experimental lesions, n = 6; two-tailed paired t test, *, P < 0.05. Scale bars: 10 µm. (E) AZD3514 pretreatment inhibits WM1366 melanoma tumorigenesis. Top
left: Tumor size, measured by digital caliper (mass = [length × width × height] × π/6) together with representative low-magnification H&E images of the
retrieved lesions. Double IF analysis of lesions with antibodies against AXL (green), for melanoma cell identification, and Ki67-positive cells (lower left). Shown
are representative images of AXL-positive cells stained with Ki67 together with relative quantification (counting in each case >50 cells in three to five fields on
digitallyretrieved images, using ImageJ). Right: Double IF analysis of lesions with antibodies against AXL, CD45, and F4/80, for melanoma cell, hematopoietic
cell, and macrophage identification, respectively. Shown are representative images together with quantification of number of F4/80-positive cells per AXL
positive tumor area (counting in each case three to four fields). Control versus experimental lesions, n = 16; two-tailed paired t test, *, P < 0.05; **, P < 0.01; ***,
P < 0.005. Scale bars: 10 µm.
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Provided online are six tables. Table S1 is a summary of patient information of tissue microarray (related to Fig. 1). Table S2 is a
summary of a panel of human melanoma cell lines used in this study (related to Fig. 1). Table S3 lists 155 genes up- or
down-modulated by AR silencing in three melanoma cell lines (WM1366, SKMEL28, and WM115) from transcriptomic profiling
(related to Fig. 3). Table S4 lists gene sets significantly associated with differentially expressed genes in melanoma cells upon AR
gene silencing (related to Fig. 3). Table S5 lists perturbagenswith concordance with AR signatures, including the associated P values
from iLINCS database (related to Fig. 3). Table S6 lists reagents and resources.
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